WM Artphoto, Maria Westling

We are a research-based company in the cancer diagnostic field. We have developed ColoNode® – a biomarker test for accurate detection and characterization, of cancer cells in lymph nodes of colorectal cancer patients.

Colorectal cancer is the third most common cancer worldwide. Half of all patients die from the disease, despite available treatments. Additional chemotherapy following surgery can reduce the risk of recurrent cancer, but the currently used methods for selecting patients for different treatment options are inaccurate and ineffective. This results in both over- and undertreatment with unnecessary human suffering and high costs.

HiloProbe has developed ColoNode to identify each patient’s need of treatment after surgery for colorectal cancer. Examination of lymph node tissue with ColoNode® offers clinicians an objective and accurate routine for detection of cancer cells and determination of their aggressiveness.

HiloProbe has raised an additional 3 million kronor in funding from existing owners

HiloProbe has raised an additional 3 million kronor in funding from existing owners. This capital injection is a step towards achieving the next goal. ”The main focus of this capital injection is to initiate sales, which will enable us to attract a larger amount of...

New study confirms HiloProbe’s ColoNode kit improves colon cancer diagnostics

Swedish biotech company HiloProbe says it has reached a significant milestone after the results of a prospective multicenter study conducted in collaboration with Umeå University and eight Swedish hospitals were published in the International Journal of Cancer. The...

THOMAS BUSCH APPOINTED NEW CHAIRMAN OF THE BOARD AT HILOPROBE AB

Thomas Busch has taken over as Chairman of the Board at Swedish biotech company Hiloprobe AB at what he calls “an exciting time” for the thriving business. “We are now ready to transition from a research company to actively marketing and selling our ColoNode biomarker...

New promising ColoNode results

Umeå University, has in collaboration with HiloProbe AB completed the first part of a new clinical study of its ColoNode biomarker test, which provides further important evidence for the product ColoNode's benefits and usefulness in colon cancer. “The results look...

HiloProbe enters strategically important partnership with Biocartis

We are very happy to start a collaboration and a long-term relationship with Biocartis, which strengthens our focus on colorectal cancer thanks to Biocartis’ established sales and distribution network across many countries. For more information please read Biocartis...

Funded by